ARTICLE | Clinical News

Remura low concentration bromfenac: Phase III started

September 20, 2010 7:00 AM UTC

Ista began a pair of double-blind, placebo-controlled, U.S. Phase III trials to evaluate 2 doses of Remura in about 1,000 patients with mild to moderate dry eye disease over 42 days. The company has a...